Association of Proton Pump Inhibitors with Risk of Hepatic Encephalopathy in Advanced Liver Disease: A Meta-analysis

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2019 Jun 19

PMID 31210719

Citations 8

Authors

Xin-Xing Tantai

Long-Bao Yang

Zhong-Cao Wei

Cai-Lan Xiao

Li-Rong Chen

Jin-Hai Wang

Na Liu

Affiliations

Soon will be listed here.

Abstract

Background: Several studies have explored the association between the use of proton pump inhibitors (PPIs) and the risk of developing hepatic encephalopathy (HE) in patients with advanced liver disease. However, the evidence-based conclusions are controversial. We hypothesized that using PPIs may increase the risk of HE in patients with advanced liver disease. If confirmed, clinicians must strictly adhere to the indications for PPI treatment in this population.

Aim: To evaluate the pooled risk of HE in patients with advanced liver disease who use PPIs.

Methods: Three electronic databases (PubMed, EMBASE, and the Cochrane Library) were searched from the date of database inception through January 8, 2019 to identify comparative studies evaluating the association between PPI use and the risk of HE. Data from the included studies were extracted. The random-effects model was used for pooling risk estimates and the corresponding 95% confidence intervals (CIs). Subgroup and sensitivity analyses were also performed.

Results: In total, 4342 patients from five case-control studies and 188053 patients from four cohort studies were included in this analysis. In patients with advanced liver disease, PPI use was associated with an elevated risk of developing HE, with significant heterogeneity. The pooled odds ratio for case-control studies was 2.58 (95%CI: 1.68-3.94, = 72%). The pooled RR for cohort studies was 1.67 (95%CI: 1.30-2.14, = 67%). The results of the subgroup analyses suggested that the heterogeneity may be the result of differences in the study designs and the definitions of PPI use. The sensitivity and subgroup analyses did not alter our findings.

Conclusion: In patients with advanced liver disease, PPI use is associated with an elevated risk of HE. Future large prospective studies are needed to confirm this association.

Citing Articles

Proton Pump Inhibitors in Patients with Cirrhosis: Pharmacokinetics, Benefits and Drawbacks.

El-Azab G Curr Gastroenterol Rep. 2024; 26(12):323-334.

PMID: 39167119 DOI: 10.1007/s11894-024-00943-7.

Forgettable in the care of liver cirrhosis: the unseen culprits of progression from bad to worse.

Elsabaawy M, Alhaddad O Prz Gastroenterol. 2024; 19(1):6-17.

PMID: 38571544 PMC: 10985753. DOI: 10.5114/pg.2024.136361.

Association between proton pump inhibitors and risk of hepatic encephalopathy in patients undergoing transjugular intrahepatic portosystemic shunt: a protocol for a systematic review and meta-analysis.

Su Y, Chen Y, Zheng J, Yao C BMJ Open. 2024; 14(4):e078412.

PMID: 38569689 PMC: 10989172. DOI: 10.1136/bmjopen-2023-078412.

Adverse Effects Associated with Long-Term Use of Proton Pump Inhibitors.

Maideen N Chonnam Med J. 2023; 59(2):115-127.

PMID: 37303818 PMC: 10248387. DOI: 10.4068/cmj.2023.59.2.115.

Electroencephalography Signatures for Hepatic Encephalopathy in Cirrhosis Patients Treated with Proton Pump Inhibitors: An Exploratory Pilot Study.

Zhang P, Zhou L, Chen L, Zhang Z, Han R, Guo G Biomedicines. 2022; 10(12).

PMID: 36551796 PMC: 9776374. DOI: 10.3390/biomedicines10123040.

References

Ishizaki T, Horai Y . Review article: cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole. Aliment Pharmacol Ther. 1999; 13 Suppl 3:27-36. DOI: 10.1046/j.1365-2036.1999.00022.x. View

Stroup D, Berlin J, Morton S, Olkin I, Williamson G, Rennie D . Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000; 283(15):2008-12. DOI: 10.1001/jama.283.15.2008. View

Barrison A, Jarboe L, Weinberg B, Nimmagadda K, Sullivan L, Wolfe M . Patterns of proton pump inhibitor use in clinical practice. Am J Med. 2001; 111(6):469-73. DOI: 10.1016/s0002-9343(01)00901-9. View

Schulz K, Grimes D . Case-control studies: research in reverse. Lancet. 2002; 359(9304):431-4. DOI: 10.1016/S0140-6736(02)07605-5. View

Osawa H, Kita H, Ohnishi H, Hoshino H, Mutoh H, Ishino Y . Helicobacter pylori eradication induces marked increase in H+/K+-adenosine triphosphatase expression without altering parietal cell number in human gastric mucosa. Gut. 2005; 55(2):152-7. PMC: 1856523. DOI: 10.1136/gut.2005.066464. View

Kalaitzakis E, Bjornsson E . Inadequate use of proton-pump inhibitors in patients with liver cirrhosis. Eur J Gastroenterol Hepatol. 2008; 20(6):512-8. DOI: 10.1097/MEG.0b013e3282f4aa01. View

Chavez-Tapia N, Tellez-Avila F, Garcia-Leiva J, Valdovinos M . Use and overuse of proton pump inhibitors in cirrhotic patients. Med Sci Monit. 2008; 14(9):CR468-72. View

Schmidt C, Kohlmann T . When to use the odds ratio or the relative risk?. Int J Public Health. 2009; 53(3):165-7. DOI: 10.1007/s00038-008-7068-3. View

Saha A, Hammond C, Beeson C, Peek Jr R, Smolka A . Helicobacter pylori represses proton pump expression and inhibits acid secretion in human gastric mucosa. Gut. 2010; 59(7):874-81. PMC: 2980826. DOI: 10.1136/gut.2009.194795. View

10.

Gupta A, Dhiman R, Kumari S, Rana S, Agarwal R, Duseja A . Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy. J Hepatol. 2010; 53(5):849-55. DOI: 10.1016/j.jhep.2010.05.017. View

11.

Prakash R, Mullen K . Mechanisms, diagnosis and management of hepatic encephalopathy. Nat Rev Gastroenterol Hepatol. 2010; 7(9):515-25. DOI: 10.1038/nrgastro.2010.116. View

12.

van Vlerken L, Huisman E, van Hoek B, Renooij W, de Rooij F, Siersema P . Bacterial infections in cirrhosis: role of proton pump inhibitors and intestinal permeability. Eur J Clin Invest. 2012; 42(7):760-7. DOI: 10.1111/j.1365-2362.2011.02643.x. View

13.

Bajaj J, Ratliff S, Heuman D, Lapane K . Proton pump inhibitors are associated with a high rate of serious infections in veterans with decompensated cirrhosis. Aliment Pharmacol Ther. 2012; 36(9):866-74. PMC: 3524366. DOI: 10.1111/apt.12045. View

14.

Lo W, Chan W . Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin Gastroenterol Hepatol. 2012; 11(5):483-90. DOI: 10.1016/j.cgh.2012.12.011. View

15.

Sahara S, Sugimoto M, Uotani T, Ichikawa H, Yamade M, Iwaizumi M . Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole. Aliment Pharmacol Ther. 2013; 38(9):1129-37. DOI: 10.1111/apt.12492. View

16.

Corleto V, Festa S, Di Giulio E, Annibale B . Proton pump inhibitor therapy and potential long-term harm. Curr Opin Endocrinol Diabetes Obes. 2013; 21(1):3-8. DOI: 10.1097/MED.0000000000000031. View

17.

Bajaj J . The role of microbiota in hepatic encephalopathy. Gut Microbes. 2014; 5(3):397-403. PMC: 4153779. DOI: 10.4161/gmic.28684. View

18.

Lin Z, Zuo Y, Hu P . Association of Proton Pump Inhibitor Therapy with Hepatic Encephalopathy in Hepatitis B Virus-related Acute-on-Chronic Liver Failure. Hepat Mon. 2014; 14(4):e16258. PMC: 3989600. DOI: 10.5812/hepatmon.16258. View

19.

Miura K, Tanaka A, Yamamoto T, Adachi M, Takikawa H . Proton pump inhibitor use is associated with spontaneous bacterial peritonitis in patients with liver cirrhosis. Intern Med. 2014; 53(10):1037-42. DOI: 10.2169/internalmedicine.53.2021. View

20.

Merli M, Lucidi C, Di Gregorio V, Giannelli V, Giusto M, Ceccarelli G . The chronic use of beta-blockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosis. Liver Int. 2014; 35(2):362-9. DOI: 10.1111/liv.12593. View